phase readout
savePhase 3 primary completion: Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
November 1, 2031updated 8d ago
community read0 votes
Sponsor: Kura Oncology, Inc.. Status: Recruiting. Conditions: Acute Myeloid Leukemia (AML). NCT07007312.
view source ↗Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that